Angela Sormani
Microsoft, Jerusalem Venture Partners and Akamai Technologies, a provider of cloud services have launched a cybersecurity accelerator. The program is located at the Microsoft Ventures Accelerator in Tel Aviv.
Federal prosecutor Marc P. Berger has joined the New York office of Ropes & Gray. He will be a partner in Ropes & Gray's government enforcement practice.
Neuberger Berman has appointed Clifford Chiu, a former partner member at KKR, as senior adviser to Neuberger Berman Asia, effective immediately. Chiu will work across the Asia Pacific region to help Neuberger Berman build its Asian client base.
UK-based Admedo has raised a $2 million round of series A funding. The round was led by Sussex Place Ventures. Playfair Capital, Encore Capital and Kima Ventures also participated. Admedo enables advertisers and agencies to manage their programmatic advertising in-house.
This morning there are billion dollar deals aplenty with Carlyle and CVC on the cusp of acquisitions, Sankaty acquiring JPMorgan's mezzanine portfolio and IPOs having their strongest week since 2000.
Thinknum has closed a $1 million seed round led by Pejman Mar Ventures. Thinknum builds financial analysis products that streamline the investing process by facilitating collaboration and providing easy access to data.
This week there are associate, managing director and manager of finance positions up for grabs at Alliance Bernstein, State Street, SVB and Vista Equity Partners.
Los Angeles-based venture capital firm Bam Ventures is seeking $10 million for Bam Ventures Partners according to a regulatory filing.
Sankaty Advisors has acquired a portfolio of loans and other securities from J.P. Morgan’s Global Special Opportunities Group. The portfolio contains mezzanine loans in North America and Europe, as well as loans and related special situations investments in Australia and across Asia, with an aggregate value of approximately $1.3 billion.
Emulate has secured a $12 million Series A financing. Emulate is focused on commercializing Organs-on-Chips to achieve a new standard for mimicking true human physiology so that responses to medicines, chemicals and diseases can be accurately predicted. The Series A was led by NanoDimension with Cedars-Sinai Medical Center and private investor Hansjörg Wyss also participating.